Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck (Q39297048)

10 September 2017

title

Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck (English)

1 reference

10 September 2017

main subject

squamous cell carcinoma

1 reference

Nadia Harbeck

1

1 reference

10 September 2017

Flavio Solca

series ordinal

2

1 reference

10 September 2017

Thomas C Gauler

series ordinal

3

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 January 2014

1 reference

10 September 2017

1 reference

10 September 2017

volume

10

1 reference

10 September 2017

issue

1

1 reference

10 September 2017

page(s)

21-40

1 reference

ErbB receptors: from oncogenes to targeted cancer therapies

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Ligand-induced ErbB receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Mechanisms of ErbB receptor negative regulation and relevance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

EGFR mutations and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Afatinib (BIBW 2992) development in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

p95HER2 and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Herceptin: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

The chemoradiation paradigm in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Diarrhea associated with afatinib: an oral ErbB family blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.244

21 January 2018

Identifiers

DOI

10.2217/FON.13.244

1 reference

10 September 2017

1 reference